Fresenius Medical Care AG & Co. KGaA (ETR:FME – Get Rating) has been given a €42.00 ($43.30) target price by investment analysts at Warburg Research in a report issued on Friday, Borsen Zeitung reports. Warburg Research's target price suggests a potential upside of 15.77% from the stock's previous close.

Other research analysts have also recently issued research reports about the stock. Jefferies Financial Group set a €64.00 ($65.98) price objective on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Monday, July 25th. UBS Group set a €38.00 ($39.18) target price on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, July 29th. set a €58.00 ($59.79) target price on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, July 29th. JPMorgan Chase & Co. set a €23.00 ($23.71) target price on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, July 29th. Finally, Deutsche Bank Aktiengesellschaft set a €37.00 ($38.14) target price on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday.

Fresenius Medical Care AG & Co. KGaA Trading Down 0.3 %

FME stock traded down €0.10 ($0.10) during trading on Friday, hitting €36.28 ($37.40). The company had a trading volume of 645,041 shares, compared to its average volume of 704,197. The company has a quick ratio of 0.79, a current ratio of 1.26 and a debt-to-equity ratio of 91.78. The firm has a 50-day moving average price of €47.65 and a 200-day moving average price of €55.13. Fresenius Medical Care AG & Co. KGaA has a 12 month low of €37.37 ($38.53) and a 12 month high of €69.96 ($72.12). The stock has a market cap of $10.63 billion and a price-to-earnings ratio of 12.09.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

See Also

• Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
• Why Apple Could Be At All-Time Highs By Year End
• Beyond Meat Is Not Beyond Hope, And It's Cheap
• BJ's Wholesale Club Stock Has More Room to Grow
• 3 Hotel Stocks to Consider Checking into After Earnings

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.